0001583107 false 0001583107 2022-04-26 2022-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC  20549








Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event Reported): April 26, 2022





(Exact Name of Registrant as Specified in its Charter)




Cayman Islands   001-36033   98-1226628
(State or Other Jurisdiction of   (Commission File Number)   (I.R.S. Employer Identification
Incorporation)       Number)


PO Box 309

Ugland House, South Church Street

George Town, Grand Cayman, Cayman Islands KY1-1104

(650) 808-6000

(Addresses, including zip code, and telephone number, including area code, of principal executive offices)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Ordinary Share $0.00001 Par Value   TBPH   NASDAQ Global Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company    ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.07 Submission of Matters to a Vote of Security Holders.


(a)            The 2022 Annual General Meeting of Shareholders (the “Annual Meeting”) of Theravance Biopharma, Inc. (the “Company”) was held on April 26, 2022.


(b)            Shareholders holding 70,835,856 shares of capital stock, representing 93.33% of the total number of shares outstanding and entitled to vote at the Annual Meeting, were present in person or by proxy at the Annual Meeting.


The nominees listed below were elected Class II members of the Board of Directors with the respective numbers of shares voted set forth opposite their names:


Nominees  For   Against   Abstain   Broker Non-Votes 
Rick E Winningham   63,397,131    2,412,238    39,123    4,987,364 
Percentage of Shares Voted   96.28%   3.66%   0.06%    
Donal O’Connor   63,706,953    2,108,902    32,637    4,987,364 
Percentage of Shares Voted   96.75%   3.20%   0.05%    


The shareholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The voting results are set forth below:


   For   Against   Abstain   Broker Non-Votes 
Number of Shares Voted   69,822,946    873,738    139,172     
Percentage of Shares Voted   98.57%   1.23%   0.20%    


For more information about the foregoing proposals, see the Company’s Proxy Statement.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date:  April 28, 2022 By: /s/ Brett Grimaud
    Brett Grimaud
    General Counsel